Spiddal woman, Sheila Concannon is the first patient in Ireland to be fitted with an early warning sensor used to monitor signs of heart failure in patients, following a procedure at University of Galway, the first hospital in Ireland to introduce the device.
Designed to 'help patients suffering with heart failure to better monitor their fluids in the body', the device offers early warning signs of a patient's condition worsening, enabling earlier intervention. The procedure was carried out as part of a clinical trial led by Prof Faisal Sharif, Consultant Interventional Cardiologist at UHG.
“Traditionally we’ve relied on a patient describing symptoms, and by then they may have already progressed to the point of hospitalisation. Now we are getting crucial information about how the patient is doing and we can get it while they are at home.
"The device foretells of a fluid overload in the body 14 days before the patient has any symptoms so action can be taken to prevent the symptoms of shortness of breath, swelling of the legs and prevent hospital admission," explained Prof Sharif, adding, “Clinicians are alerted if readings are elevated beyond the thresholds. Common interventions in response to evidence of fluid build-up include review of medication and increased dosage of diuretics to reduce fluid retention, prescriptions are emailed to the patient’s local pharmacy.
"We would also have regular remote consultations with the patient if we observe any elevation in the readings. The device encourages clinicians to adjust medications earlier and prevent complications from escalating."
The patient at the core of the device, Sheila Concannon, says that the device has transformed how she manages her condition.
"Since the implant, I haven’t had to travel to hospital as often as I used to and it takes just a couple of minutes to do my readings and saves me so much time instead of coming all the way to hospital. I can’t even feel the device is there which is great. I am very thankful to Dr Sharif and his team for all their continued help and support.”
Rapid interventions
More than 10,000 new cases of heart failure are diagnosed annually in Ireland, according to medics, the condition 'is a significant public health priority with patients requiring frequent hospitalisations'.
Associated with frequent hospital admissions, patients with heart failure are 'commonly advised' to monitor signs of their conditions worsening, these signs include swelling, fatigue, shortness of breath and chest pain. Despite these measures, many patients with heart failure experience readmission to hospital due to fluid-build in the lungs.
This new sensor has been designed to measure the volume of fluid build-up, providing real-time information about a patient's heart health, allowing cardiology teams to monitor their patients remotely.
Procedure
“The procedure is very straightforward and is carried out as a day case operation. The sensor is implanted using a small catheter which is placed in a vein at the top of the leg. It is collapsed on entry so it can be pushed up into the inferior vena cava (IVC ), which carries oxygen-depleted blood back to the heart.
“The sensor is then expanded to its full size where it continuously measures the size of the IVC, which signals the amount of fluid in the body. High levels can increase the risk of breathing difficulties and a build-up of fluid in the lungs which can lead to an emergency hospital admission” said Prof Sharif.
After surgery, patients are provided with a detection belt worn across the stomach for one to two minutes a day which powers the implanted sensor using radiofrequency energy.
Data is sent daily from the patient's home to the heart failure team here in the hospital and this will alert the team to early warning signs so they can intervene before the patient’s condition worsens.
Successful trial
Ms Chris Kane, General Manager, Galway University Hospitals said, “This is yet another example of the ground-breaking innovation taking place at the hospital. The improvements in patients' quality of life, the decline in hospital stays, and the increased involvement of patients in their own treatment are indicators of the trial's success. This is a great example of providing quality care in a patient’s own home environment to a level as close as possible to a hospital visit.”
